Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Solriamfetol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.50 |
| ▸ | SCN4A known ✓ | P35499 | 2/20 | 0.47 |
| ▸ | TACR1 known ✓ | P25103 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.53 |
| ▸ | MMP2 | P08253 | 3/20 | 0.51 |
| ▸ | ALPI | P09923 | 1/20 | 0.50 |
| ▸ | XIAP | P98170 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Solriamfetol SCHEMBL4987496 | 1.00 | PKM (0.54) | PKMCYP1A2CYP2D6SMN1; SMN2NPSR1 | |
| Solriamfetol SCHEMBL28413501 | 1.00 | PKM (0.54) | PKMCYP1A2CYP2D6SMN1; SMN2NPSR1 | |
| Solriamfetol SCHEMBL8426383 | 1.00 | PKM (0.54) | PKMCYP1A2CYP2D6SMN1; SMN2NPSR1 | |
| Solriamfetol SCHEMBL42526 | 0.98 | PKM (0.56) | PKMCYP1A2CYP2D6SMN1; SMN2NPSR1 | |
| Solriamfetol SCHEMBL30929348 | 0.98 | PKM (0.56) | PKMCYP1A2CYP2D6SMN1; SMN2NPSR1 | |
| Solriamfetol SCHEMBL30929349 | 0.98 | PKM (0.56) | PKMCYP1A2CYP2D6SMN1; SMN2NPSR1 | |
| Solriamfetol SCHEMBL2739637 | 0.98 | PKM (0.56) | PKMCYP1A2CYP2D6SMN1; SMN2NPSR1 | |
| Solriamfetol SCHEMBL42525 | 0.98 | PKM (0.56) | PKMCYP1A2CYP2D6SMN1; SMN2NPSR1 | |
| Solriamfetol SCHEMBL30518836 | 0.95 | PKM (0.53) | PKMCYP1A2CYP2D6SMN1; SMN2NPSR1 | |
| Solriamfetol SCHEMBL30518840 | 0.93 | PKM (0.51) | PKMCYP1A2CYP2D6SMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250352476-A1 | FORMULATIONS OF (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | AXSOME MALTA LTD (MT) | 2025-11-20 | — | — | US | claimed |
| US-20250340509-A1 | COMPOSITIONS COMPRISING (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE AND USES THEREOF | AXSOME MALTA LTD (MT) | 2025-11-06 | — | — | US | claimed |
| US-12390419-B2 | Formulations of (R)-2-amino-3-phenylpropyl carbamate | AXSOME MALTA LTD. (MT) | 2025-08-19 | — | — | US | claimed |
| US-12384743-B2 | Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof | AXSOME MALTA LTD. (MT) | 2025-08-12 | — | — | US | claimed |
| WO-2025092882-A1 | COMBINATION OF A NORADRENERGIC α2A RECEPTOR AGONIST AND A NOREPINEPHRINE DOPAMINE REUPTAKE INHIBITOR AND USE THEREOF | IGNIS THERAPEUTICS (SUZHOU) LIMITED (CN) | 2025-05-08 | — | — | WO | claimed |
| US-20240285538-A1 | FORMULATIONS OF (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-08-29 | — | — | US | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-11998639-B2 | Formulations of (R)-2-amino-3-phenylpropyl carbamate | AXSOME MALTA LTD. (MT) | 2024-06-04 | — | — | US | claimed |
| EP-4364794-A2 | SOLVATE FORM OF (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | Axsome Malta Ltd. (MT) | 2024-05-08 | — | — | EP | claimed |
| EP-3509582-B1 | SOLVATE FORM OF (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | AXSOME MALTA LTD (MT) | 2023-12-20 | — | — | EP | claimed |
| US-20210205227-A1 | FORMULATIONS OF (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2021-07-08 | — | — | US | claimed |
| US-20210053912-A1 | Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2021-02-25 | — | — | US | claimed |
| US-10829443-B2 | Solvate form of (R)-2-amino-3-phenylpropyl carbamate | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2020-11-10 | — | — | US | claimed |
| US-20200085748-A1 | FORMULATIONS OF (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | AXSOME MALTA LTD. (MT) | 2020-03-19 | — | — | US | claimed |
| EP-3509581-A1 | FORMULATIONS OF (R | Jazz Pharmaceuticals International III Limited (BM) | 2019-07-17 | — | — | EP | claimed |
| US-20190194126-A1 | Solvate Form of (R)-2-amino-3-phenylpropyl carbamate | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2019-06-27 | — | — | US | claimed |
| US-20190117578-A1 | FORMULATIONS OF (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2019-04-25 | — | — | US | claimed |
| US-10195151-B2 | Formulations of (R)-2-amino-3-phenylpropyl carbamate | JAZZ PHARMACEUTICALS INTERNATIONAL III LIMITED (BM) | 2019-02-05 | — | — | US | claimed |
| WO-2018048862-A1 | FORMULATIONS OF ( R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | JAZZ PHARMACEUTICALS INTERNATIONAL III LIMITED (BM) | 2018-03-15 | — | — | WO | claimed |
| US-20180064652-A1 | FORMULATIONS OF (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2018-03-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240285538-A1 | FORMULATIONS OF (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | PRCP, GRPR, CPS1 | PTGS1 1208/4885SCN4A 2296/4885TACR1 34/4885 |
| US-12390419-B2 | Formulations of (R)-2-amino-3-phenylpropyl carbamate | PRCP, GRPR, CPS1 | PTGS1 1208/4885SCN4A 2296/4885TACR1 34/4885 |
| US-20250340509-A1 | COMPOSITIONS COMPRISING (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE AND USES THEREOF | APC, PKD1, PKD2 | PTGS1 3895/4885SCN4A 1149/4885TACR1 1239/4885 |
| US-20250352476-A1 | FORMULATIONS OF (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | CPS1, PRCP, GLS2 | PTGS1 2197/4885SCN4A 1361/4885TACR1 66/4885 |
| US-20180064652-A1 | FORMULATIONS OF (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | PRCP, GRPR, CPS1 | PTGS1 1208/4885SCN4A 2296/4885TACR1 34/4885 |
| US-20210205227-A1 | FORMULATIONS OF (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | PRCP, GRPR, CPS1 | PTGS1 1208/4885SCN4A 2296/4885TACR1 34/4885 |
| US-12384743-B2 | Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof | APC, PKD1, PKD2 | PTGS1 3895/4885SCN4A 1149/4885TACR1 1239/4885 |
| US-10829443-B2 | Solvate form of (R)-2-amino-3-phenylpropyl carbamate | APC, PKD1, PKD2 | PTGS1 4001/4885SCN4A 1282/4885TACR1 795/4885 |
| US-10195151-B2 | Formulations of (R)-2-amino-3-phenylpropyl carbamate | PRCP, GRPR, CPS1 | PTGS1 1208/4885SCN4A 2296/4885TACR1 34/4885 |
| US-20210053912-A1 | Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof | APC, PKD1, PKD2 | PTGS1 3895/4885SCN4A 1149/4885TACR1 1239/4885 |
| US-20190194126-A1 | Solvate Form of (R)-2-amino-3-phenylpropyl carbamate | APC, PKD1, PKD2 | PTGS1 4001/4885SCN4A 1282/4885TACR1 795/4885 |
| US-20190117578-A1 | FORMULATIONS OF (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | PRCP, GRPR, CPS1 | PTGS1 1208/4885SCN4A 2296/4885TACR1 34/4885 |
| US-20200085748-A1 | FORMULATIONS OF (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | PRCP, GRPR, CPS1 | PTGS1 1208/4885SCN4A 2296/4885TACR1 34/4885 |
| US-11998639-B2 | Formulations of (R)-2-amino-3-phenylpropyl carbamate | PRCP, GRPR, CPS1 | PTGS1 1208/4885SCN4A 2296/4885TACR1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.